Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H12F5N3O2S |
| Molecular Weight | 405.342 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=CC=C(C=C1)N2N=C(CC2C3=C(F)C=C(F)C=C3)C(F)(F)F
InChI
InChIKey=ZZMJXWXXMAAPLI-UHFFFAOYSA-N
InChI=1S/C16H12F5N3O2S/c17-9-1-6-12(13(18)7-9)14-8-15(16(19,20)21)23-24(14)10-2-4-11(5-3-10)27(22,25)26/h1-7,14H,8H2,(H2,22,25,26)
| Molecular Formula | C16H12F5N3O2S |
| Molecular Weight | 405.342 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Determination of enantiomeric purity of a novel COX-2 anti-inflammatory drug by capillary electrophoresis using single and dual cyclodextrin systems. | 2003-05 |
|
| Enantioseparation of novel COX-2 anti-inflammatory drugs by capillary electrophoresis using single and dual cyclodextrin systems. | 2002-06 |
|
| Pharmacokinetics of E-6087, a new anti-inflammatory agent, in rats and dogs. | 2001-09 |
|
| Development and validation of two chromatographic methods for the quantification of E-6087 and one of its metabolites, E-6132, in rat plasma. | 2001-03 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:53:53 GMT 2025
by
admin
on
Wed Apr 02 07:53:53 GMT 2025
|
| Record UNII |
VM9PYQ1MQG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9953093
Created by
admin on Wed Apr 02 07:53:53 GMT 2025 , Edited by admin on Wed Apr 02 07:53:53 GMT 2025
|
PRIMARY | |||
|
VM9PYQ1MQG
Created by
admin on Wed Apr 02 07:53:53 GMT 2025 , Edited by admin on Wed Apr 02 07:53:53 GMT 2025
|
PRIMARY | |||
|
300000023685
Created by
admin on Wed Apr 02 07:53:53 GMT 2025 , Edited by admin on Wed Apr 02 07:53:53 GMT 2025
|
PRIMARY | |||
|
C174926
Created by
admin on Wed Apr 02 07:53:53 GMT 2025 , Edited by admin on Wed Apr 02 07:53:53 GMT 2025
|
PRIMARY | |||
|
11305
Created by
admin on Wed Apr 02 07:53:53 GMT 2025 , Edited by admin on Wed Apr 02 07:53:53 GMT 2025
|
PRIMARY | |||
|
251442-94-1
Created by
admin on Wed Apr 02 07:53:53 GMT 2025 , Edited by admin on Wed Apr 02 07:53:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
E-6087 is a nonsteroidal anti-inflammatory compound that selectively inhibits cyclooxygenase-2. Because E-6087 has a chiral center, this compound is a racemic mixture of two stereoisomers, (+)-(R)-E-6087 (E-6231) and (-)-(S)-E-6087 (E-6232). Peak plasma levels of E-6231 were higher than levels obtained for E-6232.
|
||
|
ACTIVE MOIETY |
E-6087,(+/-) 4-(5-(2,4-difluorophenyl)-4,5-dihydro-
3-trifluoromethyl-1H-pyrazol-1-yl) benzenesulfonamide,
was synthesized and supplied by the Synthesis Department of Laboratorios Dr Esteve (Barcelona,Spain). This compound is a benzenesulfonamide that
has shown anti-inflammatory, analgesic and
antipyretic activity in animal models (Figure 1).
|
